Abstract
Correction for ‘Disulfiram as an anti-inflammatory agent: mechanisms, nano-delivery strategies, and applications in non-oncologic diseases’ by Qiwen Jiang et al., RSC Adv., 2025, 15, 36344–36364, https://doi.org/10.1039/D5RA04662A.
The authors regret that the work of Cvek et al. published in ACS Medicinal Chemistry Letters was incorrectly cited in ref. 167. The citation was erroneously inserted during referencing and unfortunately overlooked in revision. The citation has now been corrected to:
J. Lanz, N. Biniaz‑Harris, M. Kuvaldina, S. Jain, K. Lewis, B. A. Fallon, Antibiotics, 2023, 12, 524.
The authors initially described the work of Liu et al., published in Nature Immunology in 2020 (ref. 12), as “a groundbreaking discovery”. However, subsequent in-depth research has indicated that the antiseptic effect of DSF in vivo may be significantly influenced by copper, and their work did not prove that gasdermin D is inhibited in vivo by DSF specifically. Moreover, while DSF has been shown to effectively inhibit GSDMD pore formation in vitro, its in vivo efficacy in blocking this process constitutes an unresolved question. Therefore, the description “a groundbreaking discovery” may not be appropriate. The authors have revised the original text to the following more precise statement:
“A study by Liu and colleagues from the Program in Cellular and Molecular Medicine at Boston Children’s Hospital revealed that DSF specifically in vitro inhibits the pore-formation of gasdermin D (GSDMD), a key mediator of pyroptosis.12 Although it remains unclear whether DSF directly inhibits GSDMD pore formation in vivo, and whether its anti-pyroptotic effect is mediated by DSF itself or its copper-metabolite, its antiseptic effect is significant.12”
These changes do not affect the results or conclusions of this review. The authors would like to apologise for any inconvenience caused.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.